CytRx Corporation developed the Master Chaperone Regulator Assay (MaCRA) for compound screening of a large number of small molecule compounds to identify drug candidates that modify the activity of the heat shock transcription factor 1 (Hsf1).
MaCRA can be used to identify both amplifiers and inhibitors of this key repair pathway, to identify drug candidates that either protect cells from misfolded proteins (amplifiers for neurodegenerative diseases) or that make cells more susceptible to the toxicity of misfolded proteins (inhibitors for cancer). MaCRA is a quantitative image-based platform that accurately quantifies the amount of Hsf1 in stress granules.
Published in Drug Discovery & Development magazine: Vol. 11, No. 12, December, 2008, p.31.
Filed Under: Drug Discovery